BarunBGabelicTAdamecI, et al. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Mult Scler Relat Disord2020; 48: 102704.
2.
NoviGBovisFFabbriS, et al. Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurol Neuroimmunol Neuroinflamm2020; 7(5): e845.
3.
RolfesLPawlitzkiMPfeufferS, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm2021; 8(5): e1035.
4.
TazzaFLapucciCCellerinoM, et al. Personalizing ocrelizumab treatment in multiple sclerosis: What can we learn from Sars-Cov2 pandemic?J Neurol Sci2021; 427: 117501.
5.
van LieropZYTooropAAvan BallegoijWJ, et al. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult Scler. Epub ahead of print 9July2021. DOI: 10.1177/13524585211028833.
6.
VollmerBLWallachAICorboyJR, et al. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol2020; 7(9): 1477–1487.
7.
Langer-GouldASmithJBLiBH, et al. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol2021; 8: 938–943.
8.
TooropAAvan LieropZYGJStrijbisEMM, et al. The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis. Mult Scler Relat Disord. Epub ahead of print 1November2021. DOI: 10.1016/j.msard.2021.103364.
9.
GibianskyEPetryCMercierF, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol2021; 87: 2511–2520.
10.
BakerDPryceGJamesLK, et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord2020; 44: 102279.
